AbbVie Inc. (NYSE:ABBV) registered a -2.07% decrease, still its new closing price is 20.72% up from the company’s 1 year high of 66.82.It posted -1.88% losses in previous 5 sessions and is now the subject of 11 analysts who together assign a hold rating on stock. 1 of Wall Street analysts have an underperform rating; the 0 sells versus 4 buy or better ratings. The 21 stock analysts following this company have an average price target at $69.89, with individual PT in the $49.00-$90.00 range. The shares moved at $60.00, implying that brokerage firms see shares gaining about 11.54% in twelve months time.
AbbVie Inc. (ABBV) SEC Form 4 News
The stock is getting much attention these days as insiders are offloading shares while they posted a -3.22% fall year to date. A EVP, CFO at AbbVie Inc. (ABBV) offloaded shares in a transaction closed on Friday December 02, 2016. CHASE WILLIAM J sold 6,600 shares in the company at $59.19 each and collected $390,001 in proceeds. CHASE WILLIAM J now owns 172,871 shares in the company after this transaction. A VP, Controller in the company, HURWICH THOMAS A., disclosed a transaction on Wednesday November 16, 2016 that ended up generating $192,000 from the sale of 3,100 shares at $62 per share.
AbbVie Inc. (NYSE:ABBV) Upcoming Results on Tap
AbbVie Inc. will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $1.26 in that period. Sales during the quarter are predicted to arrive at $6.48 billion.
Earnings surprise history: Last quarter, the company posted approximately $6.78 billion in revenue and EPS of $1.20. The mean forecast was for $6.91 billion and $1.20 a share, respectively. One quarter earlier, revenue for the stock was at $6.39 billion, with earnings at $1.21/share.
AbbVie Inc. (ABBV) Brokerage Update
AbbVie Inc. (ABBV) is in Credit Suisse’s research list so their analyst rating change is noteworthy. These shares were downgraded to Neutral from Outperform by Credit Suisse, according to news reported on Monday October 31, 2016.Another important research note was issued by JP Morgan on Thursday September 08, 2016.The firm downgraded ABBV to Neutral from Overweight. Over the last six months and over the last three months, the shares of AbbVie Inc. (ABBV), have changed -5.49% and -0.68%, respectively.